Channel Therapeutics announces efficacy results for eye drop formulations
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 14 2025
0mins
Should l Buy ?
Clinical Trials Success: Channel Therapeutics Corporation has successfully met its endpoints in two pre-clinical trials for eye drop formulations aimed at treating acute ocular pain and chronic dry eye disease, demonstrating significant efficacy in reducing pain in animal models.
NaV1.7 Target Validation: The results support the potential of NaV1.7 as a target for various pain treatments, reinforcing the company's belief in its broad applications for pain management, as highlighted by Dr. Eric Lang, the Chief Medical Officer.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
